CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +2.7% · net new positions -4.5% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 234.07K | $68.81M | n/a | n/a |
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | n/a |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | n/a |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | n/a | −1 |
| Q2 2024 | 14 | n/a | 3.92M | $810.09M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 5.84M | +0.5% | $913.69M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 3.86M | +5.5% | $603.32M | 0.0% | ▲ Add | 2 | SEC ↗ ×18 |
| 3 | Wellington Management ✦ | 3.19M | -15.3% | $499.18M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 4 | State Street Global Advisors ✦ (passive) | 1.83M | -1.5% | $286.50M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Harris Associates (Oakmark) ✦ | 1.47M | +26.7% | $230.48M | 0.4% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.27M | +2.8% | $197.82M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 959.54K | +58.1% | $150.13M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 834.79K | n/a | $130.61M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 9 | Arrowstreet Capital ✦ | 769.44K | +33.0% | $120.39M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 634.36K | n/a | $99.25M | 0.0% | n/c | 1 | SEC ↗ ×26 |
| 11 | Millennium Management ✦ | 465.10K | -8.3% | $72.77M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 12 | Fidelity (FMR) ✦ | 413.53K | +428.0% | $64.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 13 | Gotham Asset Management ✦ | 315.75K | +17.3% | $49.40M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 14 | PRIMECAP Management ✦ | 270.54K | 0.0% | $42.33M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 265.08K | +890.7% | $39.52M | 0.0% | ▲ Add | 6 | SEC ↗ ×6 |
| 16 | Goldman Sachs Group ✦ | 239.21K | n/a | $37.43M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 17 | Marshall Wace ✦ | 138.11K | +881.5% | $21.61M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 18 | Adage Capital Partners ✦ | 134.53K | +199.0% | $21.05M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 118.03K | -79.1% | $18.47M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | T. Rowe Price ✦ | 72.86K | -2.2% | $11.40M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 67.76K | -27.7% | $10.60M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | Bridgewater Associates ✦ | 19.91K | New | $3.11M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $3.11M | 0.0% |
Exited
| Norges Bank | $76.95M | was 0.0% |
| Point72 Asset Management | $35.87M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 555 holders, 56.84M shares, $9.32B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · EVP & Chief Financial… · 10 sh @ 297.43 · $2,974
Open-market sales (S)
Officer · 981 sh · $302,580
Director · 33.56K sh · $10.07M
Officer · 2.04K sh · $599,711
Director · 573 sh · $163,443
Officer, Director · 6.50K sh · $1.82M
Officer · 3.71K sh · $1.04M
Director · 28.73K sh · $7.90M
Officer · 620 sh · $163,643
Officer · 482 sh · $127,812
Officer · 404 sh · $104,446
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology